GOTHENBURG, Sweden, April 17, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites the shareholders of Isofol Medical AB (publ), Reg. No. 556759-8064 based in Gothenburg, to the Annual General Meeting on Wednesday, May 21, 2025. The information in the press release is intended for investors. The shareholders in Isofol Medical AB (publ), […]
GOTHENBURG, Sweden, April 11, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announced that the company’s annual report and corporate governance report for the financial year 2024 are now available, in Swedish as well as an English translation, on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors.
GOTHENBURG, Sweden, April 3, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that the company’s Japanese development and commercialization partner, Solasia Pharma K.K., intends to invest approximately 140 MSEK in the upcoming phase II and III trials of arfolitixorin in Japan and a subsequent regulatory submission for the treatment of metastatic colorectal cancer.
GOTHENBURG, Sweden, March 27, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has established an advisory board with leading oncologists and colorectal cancer experts from the US, Europe and Japan. The advisors will play an important role in the continued development of the drug candidate arfolitixorin and the clinical
Isofol etablishes advisory board with leading experts Read More »
GOTHENBURG, Sweden, March 21, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the regulatory authority in Germany, BfArM, has given their final approval for the initiation of the new clinical trial of the company’s drug candidate arfolitixorin. The study will initially be conducted in Germany, where patient recruitment will commence shortly.
Isofol receives regulatory approval to initiate clinical study of arfolitixorin Read More »
GOTHENBURG, Sweden, March 17, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has expanded its network of advisors with Godefridus (Frits) J. Peters, a prominent expert on the pharmacology of anticancer treatments and key opinion leader (KOL) active at the Amsterdam University Medical Center and other institutions. The information
Isofol expands network of advisors with prominent expert Read More »
GOTHENBURG, Sweden, March 12, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that the company’s CEO will present the company and its drug candidate arfolitixorin at Stora Aktiedagarna in Stockholm today, Wednesday March 12. The information in the press release is intended for investors. Today, Wednesday, March 12, at 1:30-1:55 p.m., Petter Segelman
Isofol presents at Stora Aktiedagarna on March 12 Read More »
GOTHENBURG, Sweden, March 5, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that the company will participate in several investor and partnering meetings during the spring, to present the company and its drug candidate arfolitixorin. The information in the press release is intended for investors. Isofol’s CEO Petter Segelman Lindqvist will present Isofol
Isofol presents at several upcoming investor meetings Read More »
GOTHENBURG, Sweden, February 19, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s year-end report for January – December 2024 is now available on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. CEO’s comment ” At the end of 2024, we received positive feedback
Isofol Medical AB (publ) publishes year-end report, January – December 2024 Read More »
GOTHENBURG, Sweden, February 3, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that Roger Tell has been appointed Chief Medical Officer at Isofol ahead of the initiation of the planned clinical study. The information in the press release is intended for investors. Dr. Roger Tell (MD, PhD) has been active at Isofol
